BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth quarter and full year 2021. A briefing by BerGenBio's senior management team will take place at 10:00am CET today via a webcast presentation, followed by a Q&A session. Please see below for details. Operational Highlights – fourth quarter 2021 (including post-period end) · Post-period end, BerGenBio announced its participation in the EU-SolidAct trial, part